Netherlands· NL-5c858cec1dff
Ekterly 300 mg filmomhulde tabletten
A sebetralstat product containing sebetralstat, registered in Netherlands by Kalvista Pharmaceuticals (Ireland) Limited. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sebetralstat is registered in 9 of 19 countries.
Countries holding a registration under ATC B06AC08 (sebetralstat), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Sebetralstat · ATC B06AC08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Switzerlandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SEBETRALSTAT
- Manufacturer
- Kalvista Pharmaceuticals (Ireland) Limited
- Country
- Netherlands (NL)
- ATC code
- B06AC08
- ATC class
- Sebetralstat
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1975
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sebetralstat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEKTERLYKalVista Pharmaceuticals (Ireland) Ltd., Dublin
- SwitzerlandEkterly 300 mg, FilmtablettenKalVista Pharmaceuticals Switzerland GmbH
- IrelandEkterly 300 mg film-coated tabletsKalvista Pharmaceuticals (Ireland) Limited
- IcelandEkterlyKalvista Pharmaceuticals (Ireland) Limited
- PolandEkterlyKalVista Pharmaceuticals (Ireland) Ltd.
- BelgiumEkterly 300 mgKalvista Pharmaceuticals (Ireland)
- SwedenEkterly 300 mg Filmdragerad tablettKalvista Pharmaceuticals (Ireland) Limited
- FinlandEkterlyKalvista Pharmaceuticals (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ekterly
- Liechtenstein · Ekterly
- Norway · Ekterly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/596c80f1-c365-4ba2-a955-eb352133734e GET /v1/drugs/596c80f1-c365-4ba2-a955-eb352133734e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ekterly-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sebetralstat",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133914",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"COPOLYMEER VAN MACROGOL (25,0)-POLY(VINYL ALCOHOL) (75,0) (E 1209)",
"CROSCARMELLOSE NATRIUM (E 468)",
"GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
"GUAR GOM (E 412)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ZWART (E 172)",
"MAGNESIUMSTEARAAT (E 470b)",
"MALTODEXTRINE",
"POLYVINYLALCOHOL (E 1203)",
"POVIDON K 30 (E 1201)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)",
"TRIGLYCERIDEN MIDDELLANGE KETEN"
],
"substances": [
"SEBETRALSTAT"
],
"leaflet_url": null,
"authorised_at": "2025/09/17",
"procedure_number": "EMEA/H/C/006211",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1975",
"additional_monitoring": "Y"
}See everything about sebetralstat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.